NCT01600898|CompletedDMC
Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers
DELPHI-2
Screening and Risk Factors of Pulmonary Arterial Hypertension in BMPR2 Mutation Asymptomatic Carriers
Loading search results
DELPHI-2
Screening and Risk Factors of Pulmonary Arterial Hypertension in BMPR2 Mutation Asymptomatic Carriers
Sponsor study identifier
Secondary identifiers
OTHER · PHRC 2010
observational
55
1 country
1
Study Start
March 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2016
Actual (reported)Study Completion
July 2016
Actual (reported)In this prospective study, the investigators will implement a systematic screening program and 3-year follow-up in a cohort of asymptomatic BMPR2 mutation carriers. This study is designed to:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2016
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2012
Date type not reportedThis date has not been verified as actual or estimated.
May 15, 2012
Actual (reported)May 17, 2012
Actual (reported)July 2016
Actual (reported)July 2016
Actual (reported)predictive factors of the occurrence of PAH
follow prospectively a cohort of asymptomatic BMPR2 mutation carriers to determine predictive factors of the occurrence of PAH.
2 years
Evolution of characteristics of asymptomatic BMPR2 mutation carriers
2 years
Asymptomatic BMPR2 mutation carriers
asymptomatic BMPR2 mutation carriers.
David Montani
Le Kremlin-Bicêtre, 94270, France
Montani D, Girerd B, Jais X, Laveneziana P, Lau EMT, Bouchachi A, Hascoet S, Gunther S, Godinas L, Parent F, Guignabert C, Beurnier A, Chemla D, Herve P, Eyries M, Soubrier F, Simonneau G, Sitbon O, Savale L, Humbert M. Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. Eur Respir J. 2021 Jul 22;58(1):2004229. doi: 10.1183/13993003.04229-2020. Print 2021 Jul.
Gerges C, Beurnier A, Jais X, Herve P, Lau EMT, Girerd B, Gunther S, Bouchachi A, Jevnikar M, Boucly A, Bogaard HJ, Simonneau G, Sitbon O, Savale L, Chemla D, Humbert M, Montani D. Role of Exercise Hemodynamics in the Prediction of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers. Chest. 2024 Nov;166(5):1173-1183. doi: 10.1016/j.chest.2024.06.3808. Epub 2024 Jul 24.
David Montani, Md, PhD
Assistance-Publique Hôpitaux de Paris, Hôpital Bicêtre, Service de pneumologie
55 participants (actual enrollment reported by the registry).
First Submitted
May 15, 2012
First Posted
May 17, 2012
Study Start
March 2012
Date type not reportedThis date has not been verified as actual or estimated.
Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
Contact the study team to confirm eligibility.
Primary Completion
July 2016
Actual (reported)Study Completion
July 2016
Actual (reported)Last Updated
January 13, 2021
Record last verified: 2019-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: